MedTrace Logo

A Study of QL1706 Combined with Nine HPV Vaccine As First-line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer

NCT06882447 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-03-28

No results posted yet for this study

Summary

The study medications were used as follows: 1 cycle every 21 days (3 weeks) of the following regimen.

Test drug: QL1706, HPV 9-valent vaccine

QL1706: Dose: 5 mg/kg ; intravenous infusion (ivgtt), administered on Day 1 of each cycle and every 3 weeks (21 days).

Treatment will continue until loss of clinical benefit, occurrence of intolerable toxicity, patient or physician decision to discontinue treatment, death of the patient receiving the experimental treatment, or completion of 2 years of dosing (35 dosing cycles), withdrawal of informed consent by the subject, pregnancy of the subject, noncompliance with protocol or procedural requirements, or for administrative reasons.

HPV 9-valent vaccine: 1st dose 1 day prior to first QL1706 administration; 2nd dose 2 months after 1st dose; 3rd dose 6 months after 1st dose.

Conditions

  • Cervical Cancer Stage IVB

Interventions

DRUG

Trial drug: QL1706, HPV 9-valent vaccine

QL1706: Dose: 5 mg/kg ; intravenous infusion (ivgtt), administered on day 1 of each cycle and once every 3 weeks (21 days).

Sponsors & Collaborators

  • Northern Jiangsu People's Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2027-12-31
Completion
2028-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06882447 on ClinicalTrials.gov